The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

The deal involves an enterprise value of $85 million plus approximately $75 million in net cash held by FibroGen in China at the time of closing, totaling around $160 million. This strategic move will ...

AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

FibroGen, Inc. has announced the sale of its Chinese subsidiary to AstraZeneca, including the rights to roxadustat in China.